早期宫颈癌仅行前哨淋巴结活检而不行淋巴结清扫的生存评估:真实世界数据
基于美国国家癌症数据库的回顾性队列研究纳入465例早期宫颈癌患者,比较仅行前哨淋巴结活检(SLN活检)与SLN活检加淋巴结清扫的总体生存。5年总体生存率分别为98.6%与96.8%(P=0.69),校正后风险比为0.94(95%CI 0.24-3.67),提示仅行SLN活检可能对短期总体生存无负面影响,需进一步验证。
要点
- 早期宫颈癌仅行SLN活检组5年总体生存率为98.6%,SLN活检加淋巴结清扫组为96.8%,两组无显著差异(P=0.69)。
- 校正后风险比为0.94(95%CI 0.24-3.67),提示仅行SLN活检相比加行淋巴结清扫对总体生存可能无负面影响。
- 作者认为结果需进一步验证。
核心结论
- 美国真实世界数据提示,符合PHENIX-I试验标准的早期宫颈癌仅行SLN活检而不行淋巴结清扫可能对短期总体生存无负面影响,需进一步验证。
研究设计与样本
- 回顾性队列研究,查询美国癌症委员会国家癌症数据库,纳入2012至2022年接受初次根治性子宫切除术和SLN活检的465例18-65岁宫颈癌患者(术前分期IA1伴淋巴血管间隙浸润、IA2、IB1和IIA1,肿瘤大小≤3 cm)。
- 暴露为SLN活检时是否加行淋巴结清扫:仅SLN活检组231例,SLN活检加淋巴结清扫组234例。
- 结局为总体生存,采用Cox比例风险回归模型校正术前因素衍生的倾向性评分及术后混杂因素(病理性淋巴结转移、放疗和化疗)。
主要发现
- 仅SLN活检组5年总体生存率为98.6%(95%CI 94.3-99.7),SLN活检加淋巴结清扫组为96.8%(95%CI 93.0-98.6),P=0.69。
- 仅SLN活检相比SLN活检加淋巴结清扫的校正风险比为0.94(95%CI 0.24-3.67)。
- 探索性分析显示,鳞状细胞组织学、术前IB1期且肿瘤大小≤3 cm以及机器人辅助手术的结果相似(所有P>0.05)。
临床怎么用
- 作者认为,符合PHENIX-I试验标准的早期宫颈癌仅行SLN活检而不行淋巴结清扫可能对短期总体生存无负面影响,需进一步验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The PHENIX-I clinical trial in China demonstrated that sentinel lymph node (SLN) biopsy alone without additional lymphadenectomy for early cervical cancer had oncologic outcomes non-inferior to SLN biopsy and additional lymphadenectomy. This study examined overall survival associated with SLN biopsy alone without additional lymphadenectomy for early cervical cancer using real-world data in the United States. METHODS: This retrospective cohort study queried the Commission-on-Cancer's National Cancer Database. The study population included 465 patients aged 18-65 years-old with cervical cancer (preoperative stage IA1 with lympho-vascular space invasion, IA2, IB1, and IIA1 with tumor size of ≤3 cm) who underwent primary radical hysterectomy and SLN biopsy from 2012 to 2022. Exposure was additional lymphadenectomy at SLN biopsy (SLN biopsy alone n = 231, SLN biopsy and additional lymphadenectomy n = 234). Outcome measure was overall survival, assessed with Cox proportional hazard regression model adjusting for preoperative factor-derived propensity score and postoperative confounders (pathological lymph node metastasis, radiotherapy, and chemotherapy). RESULTS: The 5-year overall survival rates were 98.6% (95% confidence interval 94.3 to 99.7) for the SLN biopsy alone group and 96.8% (95% confidence interval 93.0 to 98.6) for the SLN biopsy and additional lymphadenectomy group (P = .69). Adjusted-hazard ratio for SLN biopsy alone compared to SLN biopsy and additional lymphadenectomy was 0.94 (95% confidence interval 0.24 to 3.67). Exploratory analysis showed similar results for squamous histology, preoperative stage IB1 with tumor size of ≤3 cm, and robotic-assisted surgery (all, P > .05). CONCLUSION: The results of this real-world data in the United States suggested that SLN biopsy alone without additional lymphadenectomy for early cervical cancer meeting the PHENIX-I trial criteria may not have negative effects on short-term overall survival, warranting further validation.
引用
- Matsuo K, Lee MW, Friedman EL, et al. Survival assessment of sentinel lymph node biopsy alone without lymphadenectomy for early cervical cancer in real-world data. Gynecol Oncol. 2025. PMID: 41349347. doi:10.1016/j.ygyno.2025.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。